Form 4: Apogee Therapeutics CEO Sells Shares Under 10b5-1 Plan

Apogee Therapeutics CEO Michael Henderson reported the sale of 80,000 shares under a pre-arranged 10b5-1 trading plan.

Summary

• Michael Thomas Henderson, Chief Executive Officer and Director of Apogee Therapeutics, Inc., reported a transaction involving common stock.
• On June 22, 2026, 80,000 shares of common stock were sold.
• The sale was executed under a Rule 10b5-1 trading plan adopted on August 13, 2025.
• The weighted average sale price was $132.54, with individual transactions ranging from $132.50 to $132.68.
• Following this transaction, Henderson beneficially owns 1,015,987 shares of common stock.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a slightly negative sentiment due to the significant sale of shares by the CEO, even though it was conducted under a pre-established 10b5-1 plan. This type of transaction can sometimes be interpreted as a lack of immediate confidence by insiders.

Negatives

• The CEO sold a significant number of shares (80,000), which could be perceived negatively by the market, despite being executed under a pre-planned 10b5-1 strategy.

Risks

• The sale of a large block of shares by a key executive could signal a lack of confidence in the company's near-term prospects, although the 10b5-1 plan mitigates this to some extent.
• Market perception of insider selling, even under a pre-arranged plan, can negatively impact stock price.

Future Outlook

The filing does not contain forward-looking statements or guidance. It solely reports a past transaction.

Management Comments

• The transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 13, 2025.
• The price reported is a weighted average, with shares sold in multiple transactions at prices ranging from $132.50 to $132.68, inclusive.
• The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request.

Industry Context

StockSavvy.ai notes that insider selling, even under a 10b5-1 plan, is a common event in the biotechnology sector. Investors often scrutinize these sales for potential signals about management's confidence in upcoming clinical trial results or regulatory approvals, which are critical value drivers for companies like Apogee Therapeutics.

Stakeholder Impact

• Shareholders: May view the CEO's sale of a significant number of shares with concern, potentially leading to short-term stock price pressure, despite the 10b5-1 plan. However, the plan itself is designed to provide liquidity and avoid insider trading perceptions.
• Employees: May interpret the sale as a signal from leadership, potentially affecting morale if perceived negatively.
• Creditors/Suppliers: Unlikely to be directly impacted by this specific transaction.

Next Steps

• The reporting person may continue to execute transactions under the existing Rule 10b5-1 plan.
• The company may provide further updates on executive transactions as they occur.

Key Dates

Recommendation

The filing reports a routine transaction under a 10b5-1 plan by the CEO. While insider selling can be a negative signal, the pre-planned nature of the sale mitigates concerns about trading on non-public information. Without other material news, this transaction alone does not warrant a strong buy or sell recommendation, suggesting a 'hold' position to observe further developments.

Keywords

Apogee Therapeutics, APGE, Form 4, Insider Trading, 10b5-1 Plan, Stock Sale, CEO, Michael Henderson, Beneficial Ownership